Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002733 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients With Metastatic Cancer
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002733: Completed Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
NCT00002733 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002733, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL therapeutic tumor infiltrating lymphocytes
- DRUG cimetidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1996-01 |
| Est. Completion | 2000-01 |
| Phase | Phase 2 |
What the finished NCT00002733 record still lists
NCT00002733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 4 interventions - of which aldesleukin is the first listed.
NCT00002733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002733 about?
NCT00002733 is a clinical study titled "Biological Therapy in Treating Patients With Metastatic Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial ...
What is the current status of trial NCT00002733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1996-01. Estimated completion is 2000-01.
What interventions are being tested in trial NCT00002733?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL), cimetidine (DRUG).
Who is sponsoring clinical trial NCT00002733?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002733's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia